Table 1.
Characteristics and quality of included studies
| Studya, year | Location | Design | IOL | No. of patients/eyes | Longest follow up (month) | Jadad | Newcastle-Ottawa Scale |
|---|---|---|---|---|---|---|---|
| Cochener, 2018 [9] | France | RCT |
Symfony PanOptix FineVison |
20/40 20/40 20/40 |
6 |
Randomization 1 Blindness 1 Dropouts 1 |
– |
| Mencucci, 2018 [10] | Italy | NRCS |
Symfony PanOptix Lisa tri 839MP |
20/40 20/40 20/40 |
3 | – | Selection 3 Comparability 2 Outcome 2 |
| AMO, 2017 [24] | United States | RCT |
Symfony ZCB00 |
148/296 151/302 |
6 |
Randomization 1 Blindness 2 Dropouts 1 |
– |
| Escandón-García, 2018 [18] | Portugal | NRCS |
Symfony PanOptix FineVison |
15/30 7/14 23/46 |
3 | – | Selection 3 Comparability 1 Outcome 2 |
| Monaco, 2017 [19] | Italy | RCT |
Symfony PanOptix SN60WF |
20/40 20/40 20/40 |
4 |
Randomization 2 Blindness 1 Dropouts 1 |
– |
| Pedrotti, 2016 [20] | Italy | NRCS |
Symfony ZCB00 |
25/50 15/30 |
3 | – | Selection 3 Comparability 2 Outcome 3 |
| Pilger, 2018 [21] | Germany | NRCS |
Symfony ZCB00 |
15/30 15/30 |
3 | – | Selection 3 Comparability 2 Outcome 3 |
| Ruiz-Mesa, 2017 [22] | Spain | NRCS |
Symfony FineVison |
20/40 20/40 |
12 | – | Selection 3 Comparability 2 Outcome 2 |
| Ruiz-Mesa, 2018 [23] | Spain | NRCS |
Symfony PanOptix |
14/28 20/40 |
29 | – | Selection 2 Comparability 2 Outcome 2 |
AMO Abbott Medical Optics, IOL intraocular lens, RCT randomized controlled trial, NRCS non-randomized controlled study
aFirst author or sponsor